PPAR Agonist and p38 Kinase Inhibitor Combination for Dry AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for treating dry, slowly progressing atrophic age-related macular degeneration (AMD), a leading cause of blindness, with a high unmet medical need for effective treatments.
Innovation Solution
A pharmaceutical combination comprising a PPAR agonist, such as pioglitazone, and a p38 kinase inhibitor, like pamapimod, is used to prevent or treat ophthalmic diseases, including AMD, either in combination or as a standalone compound, demonstrating a synergistic effect in standard AMD research models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for dry AMD, then current treatment options are limited, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent combines a PPAR agonist and a p38 kinase inhibitor into a single pharmaceutical composition, creating a dual-mechanism therapy that addresses multiple pathological pathways in AMD simultaneously. This combination approach resolves the contradiction by providing both expanded treatment versatility and enhanced therapeutic effectiveness through synergistic action.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing two distinct active ingredients with different mechanisms of action. This composite approach allows the medication to tackle multiple aspects of AMD pathology (inflammation, complement activation, RPE cell protection) simultaneously, thereby improving both reliability and adaptability of treatment.
2Adaptability or versatility
If no therapy is available for dry AMD, then current treatment options are nonexistent, but this creates a high unmet medical need
Solution Approach 1:
The patent employs preliminary protective actions by inhibiting p38 kinase and activating PPAR pathways before significant retinal damage occurs. This preventive approach addresses the unmet need by providing treatment that can slow or halt disease progression in early to intermediate dry AMD, making therapy available where previously none existed.
Solution Approach 2:
The pharmaceutical composition acts as an intermediary between the body's natural defense mechanisms and the pathological processes of AMD. By modulating inflammatory responses and complement activation through the dual-mechanism formulation, the treatment bridges the gap between available medications and the specific pathological needs of dry AMD.
3Reliability
If a single compound is used, then device complexity is low, but therapeutic benefit is limited
Solution Approach 1:
The patent merges two pharmacologically active compounds into a single fixed-dose formulation, delivering dual therapeutic mechanisms through one medication. This approach increases therapeutic benefit by targeting multiple pathological pathways simultaneously while maintaining manageable complexity through integrated formulation design.
Solution Approach 2:
The pharmaceutical composition is designed to perform multiple functions: inhibiting inflammation through p38 kinase inhibition, modulating lipid metabolism through PPAR activation, and protecting RPE cells. This multi-functionality resolves the contradiction by maximizing therapeutic benefit within a single unified formulation.
Data Source
AI summary
The present invention relates to a pharmaceutical combination comprising:(a) a PPAR agonist;(b) a p38 kinase inhibitor; and optionally(c) one or more pharmaceutically acceptable diluents, excipients or carriers for use in a method of preventing or treating ophthalmic diseases or disorders in a subject.